Home > Resources > Whitepapers > THE FUTURE OF TECHNOLOGY IN HEALTH AND HEALTH CARE

THE FUTURE OF TECHNOLOGY IN HEALTH AND HEALTH CARE

August 12, 2018

Over the course of the last century, the medical sciences have made remarkable strides in developing safer and more effective treatments, such as minimally invasive surgery and new drugs that can help mitigate the effects of diseases such as arthritis. While the science of medicine has advanced, the funding, organization, and the delivery of health care in Canada has not fundamentally changed since the advent of Medicare in the 1950s and 1960s.

Spotlight

Olink Bioscience

Olink Bioscience is focused on developing and commercializing enabling molecular tools for life science research and molecular diagnostics.

OTHER WHITEPAPERS

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

The US Bioeconomy

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,

Synthetic Biology Biotechnology & AgTech

whitePaper | June 8, 2022

For nearly two decades, the Future Today Institute has meticulously researched macro forces of change and the emerging trends that result. Our focus: understanding how these forces and trends will shape our futures.

Characterization and identification of glucuronide metabolites

whitePaper | April 21, 2023

This technical note demonstrates the comprehensive characterization and confident identification of glucuronide metabolites from hepatocyte incubations of midazolam. An orthogonal fragmentation mechanism was applied to generate diagnostic fragmentions for confident identification of glucuronide metabolites

Bioanalytical Techniques to Advance Biosimilars Development

whitePaper | August 22, 2022

Biosimilar therapies offer more unique approaches to treating patients with serious diseases, such as cancer.

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).